Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD-Reference-Cited by-同舟云学术

Treatment outcome and prognostic factor analysis in transplant-eligible Chinese myeloma patients receiving bortezomib-based induction regimens including the staged approach, PAD or VTD

Published:2012-06-08 Issue:1 Volume:5 Page:
ISSN:1756-8722
Container-title:Journal of Hematology & Oncology
language:en
Short-container-title:J Hematol Oncol

Author:

Chim Chor Sang, ,Lie Albert Kwok Wai,Chan Eric Yuk Tat,Liu Herman Sung Yu,Lau Ching Wa,Yip Sze Fai,Sim Joycelyn,Wan Thomas Shek-Kong,Ma Edmond Shiu-Kwan,Liang Raymond,Tse Eric,Kwong Yok-Lam

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Biology,Hematology

Link

http://link.springer.com/content/pdf/10.1186/1756-8722-5-28.pdf

Reference16 articles.

1. Richardson PG, Barlogie B, Berenson J: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003, 348: 2609-2617. 10.1056/NEJMoa030288.

2. Chim CS, Hwang YY, Pang C, Shek TW: Restoration of chemosensitivity by Bortezomib: implications for refractory myeloma. Nat Rev Clin Oncol. 2009, 6: 237-240. 10.1038/nrclinonc.2009.15.

3. Cavo M, Rajkumar SV, Palumbo A: International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011, 117: 6063-6073. 10.1182/blood-2011-02-297325.

4. Popat R, Oakervee HE, Hallam S: Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up. Br J Haematol. 2008, 141: 512-516. 10.1111/j.1365-2141.2008.06997.x.

5. San Miguel JF, Schlag R, Khuageva NK: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008, 359: 906-917. 10.1056/NEJMoa0801479.

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM;Bone Marrow Transplantation;2024-02-21

2. Prognostic Factors in 448 Newly Diagnosed Multiple Myeloma Receiving Bortezomib-based Induction: Impact of ASCT, Transplant Refusal and High-Risk MM;2023-09-08

3. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma;Hematology;2021-01-01

4. Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma;The Journal of Molecular Diagnostics;2020-05

5. Frequent methylation of the tumour suppressor miR‐1258 targeting PDL1: implication in multiple myeloma‐specific cytotoxicity and prognostification;British Journal of Haematology;2020-02-20